Reporting owner · CIK 0001873905
Tak Paul Peter
SEC Form 4 history across 1 companies, 4 transactions and 1 filings.
CEOChief Executive OfficerCandel Therapeutics, Inc.
Open-market transaction mix0% buys0 buys · 2 sales
Available history · Sep 10, 2026 – Sep 11, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
CADLCandel Therapeutics, Inc. | Tak Paul PeterCEO | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
CADLCandel Therapeutics, Inc. | Tak Paul PeterCEO | S · sale10b5-1 detectedSEC filing ↗ | -$620kView disclosure → | |
CADLCandel Therapeutics, Inc. | Tak Paul PeterCEO | S · sale10b5-1 detectedSEC filing ↗ | -$2.53MView disclosure → | |
CADLCandel Therapeutics, Inc. | Tak Paul PeterCEO | M · exercise10b5-1 detectedSEC filing ↗ | $193kView disclosure → |
Latest Form 4 facts
Quick context from source filings
Latest open-market transaction
sale at Candel Therapeutics, Inc. on Sep 11, 2026 valued at $620,891.
Review SEC filingLatest buy
No open-market insider purchase is available.
Monthly open-market activity
Last 1 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Sep 2026 | 0 | 2 | $0.00 | $3,160,783.32 | -$3,160,783.32 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Average P/S size$1.6M
Median P/S size$1.6M
Direct4
Indirect0
Sep 11, 2026sale
Filing-only signals
Deterministic matches in this insider's history
No filing-only signal badges matched this history.
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
No open-market purchases in available history
A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
3 observations · Sep 10, 2026 – Sep 11, 2026. Window ends at the latest available report, not today.
Selected observation · Sep 11, 2026113,321 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Sep 10, 2026 | 393,566 | Sep 11, 2026 | View transaction |
| Sep 10, 2026 | 172,700 | Sep 11, 2026 | View transaction |
| Sep 11, 2026 | 113,321 | Sep 11, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Tak Paul Peter Insider Activity FAQ
SEC Form 4 context
Who is Tak Paul Peter?
Tak Paul Peter is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001873905.
Which companies has Tak Paul Peter reported transactions for?
Candel Therapeutics, Inc.
When was Tak Paul Peter's latest insider buy?
No open-market insider purchase is available for this period.
When was Tak Paul Peter's latest insider sale?
sale at Candel Therapeutics, Inc. on Sep 11, 2026 valued at $620,891.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.